VOL NO REGD NO DA 1589

Sunday, February 12, 2006

HEADLINE

POLITICS & POLICIES

METRO & COUNTRY

VIEWS & OPINIONS

EDITORIAL

LETTER TO EDITOR

COMPANY & FINANCE

BUSINESS & FINANCE

TRADE/ECONOMY

LEISURE & ENTERTAINMENT

MARKET & COMMODITIES

SPORTS

WORLD

 

FE Specials

FE Education

Urban Property

Monthly Roundup

Saturday Feature

Asia/South Asia

 

Feature

13th SAARC SUMMIT DHAKA-2005

WOMEN & ECONOMY

57th Republic Day of India

US TRADE SHOW

 

 

 

Archive

Site Search

 

HOME

Science & Health
 
Vasella fear over 'market manipulation'
Haig Simonian and Andrew Jack
2/12/2006
 

          THE head of Novartis, Daniel Vasella, has called for regulators to look into hedge funds and the media after growing concerns about their roles during recent speculation over his company's takeover plans.
Dr Vasella, chairman and chief executive of Europe's second-largest pharmaceuticals group, stopped short of demanding new regulations.
But he expressed fears about an intensifying "systemic" problem, akin to the abuses revealed in relations between equity analysts and investment bankers during the dotcom boom.
"There are two parties that can potentially take advantage. The agents for the vendor, who can try to ramp up a share price by spreading rumours. And now you have the hedge funds," he told the Financial Times.
The comments came against the background of extreme volatility in the shares of Serono, the Swiss biotechnology group that is currently in play. The decline came after reports the company had failed to elicit bids from potential buyers.
Serono's share price shot up last November after the company confirmed it had hired Goldman Sachs to examine "strategic alternatives" -- code for a sale.
Novartis's shares dropped on widespread market speculation it was the most likely acquirer. Recently, at the group's annual press conference, Dr Vasella dampened such speculation by playing down the role of takeovers in his growth strategy.
Dr Vasella acknowledged the sensitivity of suggesting curbs on press freedom. But he said he had become increasingly concerned at what he described as deliberate misinformation.
"Frankly, I've been asking myself if the regulators should intervene. It is market manipulation that is happening now, because you have people saying things they know not to be true. It wouldn't hurt if a regulator started to look at this."
Dr Vasella, whose company spent more than $14bn on takeovers in the past year, denied Novartis was excessively acquisitive, and said internal research showed other drug makers had bought more.
But he admitted his own candour about industry consolidation and Novartis's recent record meant it was tipped regularly as a buyer, creating a challenge in terms of communications.
"The more vague you leave your strategy, the more freedom you have. The more you communicate, the more you become a hostage to fortune, and the more it can get dangerous. But saying nothing also has its price."
Under syndication arrangement
with FE

 

 
  More Headline
Over 42 per cent children have sleep problems
Iraq steps up bird flu fight with US help
IRRI to collaborate with Indian scientists on GHG effect
South Korean Presidential Aide gets money from stem cell scientist
Power and potable water using peanut shells heralds rural renewal
Vasella fear over 'market manipulation'
China to export Hepatitis A vaccines to India
 

Print this page | Mail this page | Save this page | Make this page my home page

About us  |  Contact us  |  Editor's panel  |  Career opportunity | Web Mail

 

 

 

 

Copy right @ financialexpress.com